低滴度O型全血或成分血用于创伤复苏:随机临床试验TROOP研究方案
TROOP试验为在美国15家一级创伤中心开展的实用性、多中心、贝叶斯序贯非劣效/优效性随机临床试验,计划随机纳入1100例预测需大量输血的严重创伤患者,比较低滴度O型全血与成分血复苏的效果与安全性,主要结局为6小时死亡率。
要点
- TROOP试验计划随机纳入1100例预测需大量输血的严重创伤患者。
- 主要结局为6小时死亡率,同时评估24小时及30天或住院期间死亡率等次要结局。
- 该试验旨在为低滴度O型全血在创伤患者院内管理中的效果提供高级别证据。
核心结论
- 这项大型多中心临床试验将为低滴度O型全血在预测需大量输血的创伤患者院内管理中的效果提供高级别证据。
研究设计与样本
- 实用性、多中心、贝叶斯序贯非劣效/优效性随机临床试验,在美国15家一级创伤中心开展。
- 计划随机纳入1100例预测需大量输血的严重创伤患者,随机分配至成分血复苏组或低滴度O型全血复苏组。
主要发现
- 主要结局为6小时死亡率。
- 次要结局包括24小时及30天或住院期间死亡率(取较早者)、预设并发症、裁定死亡原因、死亡时间、ICU及住院时长、无住院日、无呼吸机日及无ICU日、大手术发生率、止血时间、至止血及止血后24小时内使用的血制品数量与类型、出院去向及出院或30天时功能状态与生活质量(采用格拉斯哥昏迷评分GCS和EuroQol EQ-5D测量)。
局限性
- 现有证据仅来自观察性研究以及一项评估已不再使用类型全血的小型单中心试点随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemorrhage is the most common cause of potentially preventable death after injury. Balanced transfusion with red blood cells, plasma, and platelets (component therapy, CT) has been shown to reduce mortality, and is the standard of care. Low-Titer Group O Whole Blood (LTOWB) is an attractive alternative to CT, but existing evidence comprises observational studies, and a small single center pilot randomized controlled trial, which evaluated a type of whole blood that is no longer in use. The aim of the "Trauma Resuscitation with Low-Titer Group O Whole Blood Or Products" (TROOP) trial is to compare the effectiveness and safety of LTOWB and CT in critically injured patients predicted to require a large volume transfusion. METHODS: This is a pragmatic, multicenter, Bayesian, sequential non-inferiority/superiority, randomized clinical trial, performed within 15 level I trauma centers in the United States. We aim to randomize 1,100 injured patients to resuscitation with either CT or LTOWB. The primary outcome is 6-h mortality. Secondary outcomes include 24-h and 30-day or hospital mortality (whichever is earlier); prespecified complications; adjudicated cause of death; time to death; length of stay (ICU and hospital); and hospital-, ventilator- and ICU-free days; the incidence of major surgical procedures; time to hemostasis in those undergoing procedures with a hemostatic component; number and type of blood products used until hemostasis is achieved (and randomized products are discontinued), as well as after hemostasis has been achieved, to 24 h post-admission; discharge destination and functional status and quality of life at hospital discharge or 30 days, as measured by Glasgow Coma Scale (GCS) and EuroQol (EQ-5D) quality of life measurement. DISCUSSION: This large multicenter clinical trial will contribute high-level evidence on the effectiveness of Low-Titer Group O Whole Blood in the in-hospital management of trauma patients predicted to require a large volume transfusion. Trial registration National Clinical Trial Identified Number: NCT05638581. CLINICAL TRIAL REGISTRY: https://clinicaltrials.gov/study/NCT05638581 First submitted 2022-11-08.
引用
- Jansen JO, Pedroza C, Novelo LL, et al. Trauma resuscitation with Low-Titer Group O Whole Blood Or Products: study protocol for a randomized clinical trial (the TROOP trial). Trials. 2025. PMID: 40753420. doi:10.1186/s13063-025-08971-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。